Trial Profile
Estimation of Off-Label Use of XGEVA (Denosumab) Using Population-Based Databases in Denmark
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jun 2015
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone cancer; Bone metastases; Malignant hypercalcaemia; Multiple myeloma; Non-small cell lung cancer; Osteoporosis; Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Amgen
- 28 May 2015 Status changed from recruiting to completed, as reported by ClinicalTrial.gov.
- 01 Mar 2014 New trial record